Phase 2 N=45 Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Multiple Myeloma
Primary: Number of Participants With Serious and Non-serious Adverse Events — 45 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rate (ORR) — 3 percentage of participants
Phase 2 N=132 Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival — 5.3; 6.9 months
Phase 2 N=66 Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
Cannabis Dependence · Cannabis Withdrawal
Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…
Phase 2 N=57 A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
Malignant Melanoma
Primary: Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months — 38.6 percentage of participants
Phase 2 N=150 Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment
Hazardous Drinking · Cigarette Smoking
Primary: Percent Heavy Drinking Days — 11.1; 11.4 percentage of days
Phase 2 N=88 Thiamine as a Metabolic Resuscitator in Septic Shock
Septic Shock
Primary: Lactate Level 24 Hours After the First Study Medication Dose — 2.6; 2.5 mmol/L — p=0.40
Phase 2 N=12 Study of Losartan in the Treatment of NAFLD in Children
NAFLD
Primary: Change in Alanine Aminotransferase (ALT) From Baseline to End of Treatment (8 Weeks of Treatment) — 136.44; 117.40; 112.78; 89.40 U/L
Phase 2 N=9 Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Cigarette Smoking · Schizophrenia
Primary: Change of ExpiredCO Level From Baseline — -2.88; 9.5; -17.38; -11.5 ppm
Phase 2 N=16 Oral Immunotherapy (OIT) for Peanut Allergy
Peanut Hypersensitivity
Primary: Percentage of Subjects Achieving Tolerance as Defined by a Negative DBPCFC 4 Weeks After Discontinuation of Peanut OIT Therapy. — 89 percentage of participants
Phase 2 N=30 Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Corneal Neovascularization · Corneal Graft Failure
Primary: Number of Participants With Graft Failure at Week 39 and 52 — 0; 1; 1; 1 Participants
Phase 2 N=59 Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
Pancreatic Cancer
Primary: To Determine the Rate of (Grade 2 or Greater) Gastrointestinal Toxicity Attributable to Gemcitabine and Fractionated SBRT at One Year. — 5 Number of toxicities.
Phase 2 N=36 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Relapsed or Refractory Hodgkin Lymphoma · Relapsed or Refractory Anaplastic Large-cell Lymphoma
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (Phase 1) — 3; 9; 0; 4 Participants
Phase 2 N=23 Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Adult Grade I Meningioma · Adult Grade II Meningioma · Adult Grade III Meningioma
Primary: 6 Months - Progression-free Survival According to Response Evaluation Using Macdonald Criteria — 29.4 percentage of participants
Phase 2 N=57 Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Blastic Phase Chronic Myelogenous Leukemia
Primary: Number of Participants With Treatment Safety Failure — 13 Participants